• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

LOW MOLECULAR WEIGHT HEPARINS.

作者信息

Sharma S K

机构信息

Reader, Medicine, Armed Forces Medical College, Pune 411 040.

出版信息

Med J Armed Forces India. 1998 Jul;54(3):285-286. doi: 10.1016/S0377-1237(17)30571-3. Epub 2017 Jun 26.

DOI:10.1016/S0377-1237(17)30571-3
PMID:28775503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5531654/
Abstract
摘要

相似文献

1
LOW MOLECULAR WEIGHT HEPARINS.低分子量肝素
Med J Armed Forces India. 1998 Jul;54(3):285-286. doi: 10.1016/S0377-1237(17)30571-3. Epub 2017 Jun 26.
2
New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?肝素的新治疗机遇：低分子量肝素能提供什么？
J Thromb Thrombolysis. 1996;3(2):145-149. doi: 10.1007/BF00132407.
3
From unfractionated heparins to low molecular weight heparins.从普通肝素到低分子量肝素。
Acta Chir Scand Suppl. 1990;556:42-50.
4
Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.低分子量肝素的寡糖图谱分析：结构与活性差异
J Med Chem. 1990 Jun;33(6):1639-45. doi: 10.1021/jm00168a017.
5
Low molecular weight heparins--state-of-the-art and unsolved issues.低分子量肝素——现状与未解决的问题。
Blood Coagul Fibrinolysis. 1993 Dec;4 Suppl 1:S17-9.
6
Are all low molecular weight heparins equivalent in the management of venous thromboembolism?在静脉血栓栓塞症的治疗中，所有低分子量肝素都等效吗？
Clin Appl Thromb Hemost. 2008 Oct;14(4):385-92. doi: 10.1177/1076029608319881.
7
The use of low-molecular-weight heparins in pregnancy--how safe are they?孕期使用低分子量肝素——它们有多安全？
Curr Opin Obstet Gynecol. 2007 Dec;19(6):573-7. doi: 10.1097/GCO.0b013e3282f10e33.
8
Feasibility study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins.
J Pharm Sci. 1994 Feb;83(2):197-201. doi: 10.1002/jps.2600830216.
9
Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.低分子量肝素在不稳定型心绞痛和非Q波急性心肌梗死患者治疗中的作用。
Am J Cardiol. 2000 Apr 27;85(8A):2C-9C. doi: 10.1016/s0002-9149(00)00879-1.
10
A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.一项比较低分子量肝素与普通肝素治疗不稳定型心绞痛的对照临床试验的荟萃分析。
Indian Heart J. 2001 Mar-Apr;53(2):197-202.

引用本文的文献

1
Multifunctional applications and research advances of low-molecular-weight heparin.低分子量肝素的多功能应用及研究进展
Front Pharmacol. 2025 May 21;16:1585762. doi: 10.3389/fphar.2025.1585762. eCollection 2025.
2
Optimizing therapeutic enoxaparin in preterm neonates and infants.优化早产儿和婴儿的依诺肝素治疗
Thromb Res. 2025 Jan;245:109214. doi: 10.1016/j.thromres.2024.109214. Epub 2024 Nov 13.
3
Pulmonary Embolism in Critically Ill Patients-Prevention, Diagnosis, and Management.危重症患者的肺栓塞——预防、诊断与管理
Diagnostics (Basel). 2024 Oct 3;14(19):2208. doi: 10.3390/diagnostics14192208.
4
Suppressing upregulation of fibrinogen after polytrauma mitigates thrombosis in mice.抑制多发伤后纤维蛋白原的上调可减轻小鼠血栓形成。
J Trauma Acute Care Surg. 2024 Sep 6. doi: 10.1097/TA.0000000000004442.
5
Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2-infected endothelial model.新型冠状病毒2感染的内皮细胞模型中的纤维蛋白凝块特征及抗凝反应
EJHaem. 2022 Mar 22;3(2):326-334. doi: 10.1002/jha2.407. eCollection 2022 May.
6
Heparan Sulfate, Mucopolysaccharidosis IIIB and Sulfur Metabolism Disorders.硫酸乙酰肝素、黏多糖贮积症IIIB与硫代谢紊乱
Antioxidants (Basel). 2022 Mar 30;11(4):678. doi: 10.3390/antiox11040678.

本文引用的文献

1
Low-molecular-weight heparins.低分子量肝素
N Engl J Med. 1997 Sep 4;337(10):688-98. doi: 10.1056/NEJM199709043371007.
2
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.低分子量肝素与普通肝素治疗不稳定型冠状动脉疾病的比较。皮下注射依诺肝素治疗非Q波冠状动脉事件研究组的疗效与安全性。
N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702.
3
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.与在家皮下注射低分子量肝素相比，在医院静脉注射普通肝素治疗静脉血栓形成。塔斯曼研究小组。
N Engl J Med. 1996 Mar 14;334(11):682-7. doi: 10.1056/NEJM199603143341102.
4
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.低分子量肝素治疗深静脉血栓形成的荟萃分析。
Arch Intern Med. 1995 Mar 27;155(6):601-7.
5
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.接受低分子量肝素或普通肝素治疗的患者发生肝素诱导的血小板减少症。
N Engl J Med. 1995 May 18;332(20):1330-5. doi: 10.1056/NEJM199505183322003.
6
A meta-analysis of methods to prevent venous thromboembolism following total hip replacement.全髋关节置换术后预防静脉血栓栓塞方法的荟萃分析。
JAMA. 1994 Jun 8;271(22):1780-5.
7
Heparin kinetics in venous thrombosis and pulmonary embolism.肝素在静脉血栓形成和肺栓塞中的动力学。
Circulation. 1976 Apr;53(4):691-5. doi: 10.1161/01.cir.53.4.691.